L&K BIOMED (156100) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, L&K BIOMED (156100) reported revenue of 38.9 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202538.9 billion KRW715 million KRW-16.8 billion KRW[source]
202436.1 billion KRW3.1 billion KRW9.2 billion KRW[source]
202329.9 billion KRW2.0 billion KRW-5.2 billion KRW[source]
202219.8 billion KRW-13.1 billion KRW-16.2 billion KRW[source]
202115.4 billion KRW-15.4 billion KRW-13.6 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025104.8 billion KRW33.7 billion KRW71.1 billion KRW[source]
202499.3 billion KRW32.2 billion KRW67.0 billion KRW[source]
202375.0 billion KRW13.0 billion KRW62.0 billion KRW[source]
202268.7 billion KRW31.3 billion KRW37.4 billion KRW[source]
202171.5 billion KRW27.8 billion KRW43.7 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice